Does the HPV Vaccine Prevent Throat Cancer?
Probably yes, especially if you get the shot before age 27. The vaccine is proven to sharply reduce vaccine-type oral HPV infections, especially HPV-16, the type behind most HPV-positive throat cancers. Now real-world data show the cancers themselves turning up far less often in vaccinated people. That's an association, not proof. But it points the same way as everything that came before it.
In a large U.S. study first published in August 2026, vaccinated people were diagnosed with head and neck cancer far less often than matched unvaccinated people. The gap was widest for the throat cancers HPV drives, and for people who got the shot by age 26. That's the piece that had been missing. Until now, the case for the vaccine against throat cancer was a chain of reasoning: HPV causes most oropharyngeal cancers, including cancers of the tonsils and the base of the tongue, and the vaccine keeps the virus from taking hold in the mouth. So those cancers should fall. What had not been shown clearly was whether that chain would show up as fewer cancer diagnoses in a very large real-world cohort.
The first link was already solid
The strongest older evidence is about infection, not cancer, and there's a reason for that. Doctors can't screen for throat cancer the way they screen for cervical cancer. There's no standard screening test and no routine precancer target to catch. A lasting oral HPV infection is the earliest step anyone can measure.
On that step, the vaccine works. National survey data on U.S. young adults showed a large drop in vaccine-type oral infections. HPV-16 is the type behind most HPV-positive throat cancers.
One catch. The vaccine prevents new infections but doesn't clear existing ones. That detail ends up deciding who benefits most.
What the new study found
The researchers used de-identified medical records from 66 U.S. healthcare organizations. Over follow-up, 40 vaccinated people developed a head and neck cancer, compared with 130 of the unvaccinated. That's roughly two-thirds lower risk.
The biggest difference was in oropharyngeal squamous cell carcinoma, the throat cancer HPV most often causes. The overall lower head-and-neck cancer risk was reported from 5 to 13 years after vaccination.
How much weight it can carry
Less than the headline suggests.
The study is observational. People who choose vaccination may differ from people who don't in ways that matching on age, sex, and health conditions can't capture, so it can't prove the vaccine caused the drop. The cancer counts are small too, which makes the exact size of the effect uncertain. And the follow-up is short for a cancer that usually shows up decades after the infection.
Still, the direction fits the evidence around it. An earlier hospital registry study found very few throat cancers in vaccinated patients. One national survey didn't find a statistically significant link with HPV-related cancers overall, but it had too few cancer cases to settle anything.
The FDA has already approved Gardasil 9, the HPV vaccine used in the U.S., to prevent oropharyngeal and other head and neck cancers. That approval is accelerated, though. It rests on the vaccine's proven effect against anogenital disease. The 2020 FDA approval letter set September 30, 2026 as the final report submission date for a confirmatory trial of persistent oral infection in men ages 20 to 45.
Why the age of the first shot matters most
The statistically clear signal in the new study was in people vaccinated between 9 and 26. People vaccinated at 27 to 45 showed no significant drop in cancer risk in the reported age split. The likely reason is the catch above: by then, many people have already been exposed, and the vaccine can't undo an infection they already carry. A microsimulation study estimated that most of the oral HPV-16 infections that go on to cause cancer in U.S. men are picked up by age 26.
But that's a population average, not a verdict on you. A 35-year-old who's unvaccinated and starting new relationships hasn't met every HPV type yet, and the vaccine can still block the ones they haven't. For that person, the shot is a real option. It just isn't the same bet it would have been at 15.
| Group | What the evidence shows | Where it leaves you |
|---|---|---|
| Ages 9 to 14 | Routine vaccination at 11 or 12, can start at 9. Two doses if they're at least 5 months apart. Given before any exposure, when protection is strongest. | The clearest throat-cancer prevention case of any age group. |
| Ages 15 to 26 | Catch-up is recommended for anyone not fully vaccinated. Three doses if starting at 15 or older. | Finishing a missed or partial series is still well within the window the new study supports. |
| Ages 27 to 45 | FDA-approved, but guidelines leave it to a discussion with a clinician. In U.S. men, modeling suggests most throat-cancer-causing oral HPV-16 infections happen earlier. | Worth weighing if you're unvaccinated and expect new partners. It guards against types you haven't met, not ones you already carry. |
Safety is not what separates the age groups. In a trial comparing women 27 to 45 with women 16 to 26, side effects were mostly arm-site reactions at similar rates in both groups, with no vaccine-related serious adverse events or deaths. CDC and FDA monitoring has not found confirmed adverse events occurring at higher-than-expected rates after HPV vaccination, except fainting. You'll be asked to stay seated for 15 minutes after the shot. A severe allergy to a previous dose or vaccine component is a reason not to get it, and vaccination is postponed during pregnancy.
What would settle it
What's still missing is a long prospective study that follows vaccinated people into the decades when these cancers actually appear. A completed oral-infection trial would help if it shows fewer persistent vaccine-type infections. The stronger answer would be fewer HPV-positive throat cancers, broken out by age at vaccination.
For now, HPV vaccination is proven to prevent key HPV infections that start these cancers, and the best real-world cancer data now point the same way, most clearly when the shot comes before 27.